A detailed history of Avantax Advisory Services, Inc. transactions in Vericel Corp stock. As of the latest transaction made, Avantax Advisory Services, Inc. holds 15,915 shares of VCEL stock, worth $690,711. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,915
Previous 13,803 15.3%
Holding current value
$690,711
Previous $757,000 6.21%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 06, 2025

BUY
$44.5 - $61.8 $93,984 - $130,521
2,112 Added 15.3%
15,915 $710,000
Q4 2024

Feb 07, 2025

BUY
$40.05 - $59.11 $9,371 - $13,831
234 Added 1.72%
13,803 $757,000
Q3 2024

Nov 13, 2024

BUY
$42.25 - $53.56 $195,659 - $248,036
4,631 Added 51.81%
13,569 $573,000
Q2 2024

Aug 09, 2024

BUY
$41.71 - $52.9 $372,803 - $472,820
8,938 New
8,938 $410,000

Others Institutions Holding VCEL

About Vericel Corp


  • Ticker VCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,178,000
  • Market Cap $2.05B
  • Description
  • Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...
More about VCEL
Track This Portfolio

Track Avantax Advisory Services, Inc. Portfolio

Follow Avantax Advisory Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avantax Advisory Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Avantax Advisory Services, Inc. with notifications on news.